FLT3 and acute myeloid leukemia: After one course of BHA treatment, the ORR of 21 patients was 52.4%, with composite complete remission rate [CRc, CR plus CR with incomplete hematologic recover (CRi)] of 38.1%, and 9 cases harbored FLT3 mutations exhibited an astonishing higher ORR than that without FLT3 mutations (66.7% vs. 16.7%), indicated BHA regimen as a well-tolerated and effective chemotherapy for patients with R/R AML, especially for FLT3 mutations.701 Another drug combination of venetoclax, azacytidine, and homoharringtonine (VAH) was executed by Jin et al. to investigate the activity and tolerability.